LL-37 in ESKAPE pathogens: biofilm prevention compared
Evidence level: Laboratory research
Research question
How does biofilm prevention differ between natural and engineered antimicrobial peptides? This study compares LL-37 with WLBU2 and antibiotics.
Research model
The researchers compared multiple antimicrobial substances against ESKAPE pathogens. They investigated biofilm prevention under experimental conditions, including concentrations below the minimum inhibitory concentration.
What was found?
LL-37 showed inhibition of biofilm formation and an adhesion-related gene response in the Pseudomonas model studied. The results differed between compounds and test conditions. The strongest effects from the overall review cannot automatically be attributed to LL-37.
Limitations and interpretation
This is not a clinical comparative study. Laboratory findings do not prove that LL-37 can replace antibiotics. A result for one bacterial species must not be generalized to all ESKAPE pathogens.
Original publication
Prevention of ESKAPE pathogen biofilm formation by antimicrobial peptides WLBU2 and LL37. PMID: 29753132. View the original publication on PubMed.
This summary is based on the available source description and abstract; it is not a complete systematic review.
All Peptidera products are intended solely for scientific research and laboratory use. Not for human or animal consumption, self-administration, diagnosis, or treatment.
Related research products
View product specifications and available batch documentation. The studies discussed were not conducted with Peptidera products and do not prove the efficacy of our products. For laboratory research only; not for human or animal consumption.